Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × icotinib × 1 year × Clear all
NCT07458919 2026-03-09

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Fuzhou General Hospital

Phase EARLY_PHASE1 Not yet recruiting
94 enrolled
Thoracic

Lung Neoplasms

NCT05263947 2026-02-24

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡